Granulocyte/macrophage-colony stimulating factor and interleukin-4 expand and activate type-1 dendritic cells (DC1) when administered in vivo to cancer patients

International Journal of Cancer

Volumn 107, Issue 2, 2003, Pages 256-261

  Kiertscher, Sylvia M ^a   Gitlitz, Barbara J ^a   Figlin, Robert A ^a   Rothi, Michael D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cancer; Dendritic cells; Granulocyte macrophage colony stimulating factor; Immunotherapy; Interleukin 4

Indexed keywords

CD123 ANTIGEN; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 4;

ANTIGEN PRESENTATION; ARTICLE; BLOOD; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CELL FUNCTION; CELL MATURATION; CELL SUBPOPULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENDRITIC CELL; DENDRITIC CELL TYPE 1; DRUG EFFECT; DRUG MECHANISM; DYSPNEA; HEADACHE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IN VITRO STUDY; IN VIVO STUDY; MALE; METASTASIS; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; TH1 CELL; TH2 CELL; THROMBOCYTOPENIA; TUMOR IMMUNITY;

ANTIGENS, CD; CASE-CONTROL STUDIES; DENDRITIC CELLS; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HLA-DR ANTIGENS; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-4; LYMPHOCYTES; MONOCYTES; NEOPLASM CIRCULATING CELLS; NEOPLASMS; PHENOTYPE; TH2 CELLS;

EID: 0141857800     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11379     Document Type: Article

References (43)

1. Freudenthal PS, Steinman RM. The distinct surface of human blood dendritic cells, as observed after an improved isolation method. Proc Natl Acad Sci USA 1990;87:7698-702.
2. Thomas R, Davis LS, Lipsky PE. Isolation and characterization of human peripheral blood dendritic cells. J Immunol 1993;150:821-34.
3. O'Doherty U, Peng M, Gezelter S, Swiggard WJ, Betjes M, Bhardwaj N, Steinman. RM. Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature. Immunology 1994;82:487-93.
4. O'Doherty U, Steinman RM, Peng M, Cameron PU, Gezelter S, Kopeloff I, Swiggard WJ, Pope M, Bhardwaj N. Dendritic cells freshly isolated from human blood express CD4 and mature into typical immunostimulatory dendritic cells after culture in monocyte-conditioned medium. J Exp Med 1993;178:1067-76.
5. + leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukoc Biol 1996;59:208-18.
6. + dendritic cells. Proc Natl Acad Sci USA 1996;93:2588-92.
7. Sallusto F, Lanzavecchia A Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-18.
8. Thoma-Uszynski S, Kiertscher SM, Ochoa MT, Bouis DA, Norgard M, Miyake K, Godowski PJ, Roth MD, Modlin RL. Activation of toll-like receptor 2 on human dendritic cells triggers induction of IL-12, but not EL-10. J Immunol 2000;165:3804-10.
9. Snijders A, Kalinski P, Hilkens CM, Kapsenberg ML. High-level IL-12 production by human dendritic cells requires two signals. Int Immunol 1998;10:1593-8.
10. Ardavin C, Martinez del Hoyo G, Martin P, Anjuere F, Arias CF, Marin AR, Ruiz S, Parrillas V, Hernandez H. Origin and differentiation of dendritic cells. Trends Immunol 2001;22:691-700.
11. Kadowaki N, Ho S, Antonenko S, de Waal Malefyt R, Kastelein RA, Bazan F, Liu, YJ. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med 2001;194:863-9.
12. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nature Immunol 2000;1:199-205.
13. Robinson SP, Patterson S, English N, Davies D, Knight SC, Reid CD. Human peripheral blood contains two distinct linkages of dendritic cells. Eur J Immunol 1999;29:2769-2778.
14. Liu YJ, Kanzler H, Sourmelis V, Gilliet M. Dendritic cell lineage, plasticity and cross-regulation. Nature Immunol 2001;2:585-9.
15. + T cell anergy by peripheral blood DC2 precursors. Eur J Immunol 2001;31:2547-57.
16. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000;95:2484-90.
17. Liu YJ, Blom B. Introduction: Th2-inducing DC2 for immunotherapy. Blood 2000;2482-3.
18. Hart DN. Dendritic cells and their emerging clinical applications. Pathology 2001;33:479-92.
19. McRae BL, Semanai RT, Hayes MP, van Seventer GA. Type I interferons inhibit dendritic cell IL-12 production and Th1 development. J Immunol 1998;160:4298-4304.
20. Hochrein H, O'Keefe M, Luft T, Vandenabeele S, Grumont RJ, Maraskovsky E, Shortman K. Interieukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med 2000;192:823-33.
21. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999;20:561-7.
22. Rissoan MC, Soumelis V, Kadowski N, Grouard G, Briere F, de Waal Malefyt R, Liu, YJ. Reciprocal control of T helper and dendritic cell differentiation. Science 1999;283:1183-6.
23. + peripheral blood dendritic cells are differentially regulated by cytokines. J Immunol 1999;163:3250-9.
24. Gabrilovich DI, Corak J, Ciernik IF, Kavanaugh D, Carbone DP. Decreased antigen presentation by dendritic cells in patients with breast cancer. Clin Cancer Res 1997;3:483-90.
25. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166:678-89.
26. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI. Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000;6:1755-66.
27. Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000;164:1269-76.
28. Ohm JE, Shurin MR, Esche C, Lotze MT, Carbone DP, Gabrilovich DI. Effect of vascular endothelial growth factor and FLT3 ligand on dendritic cell generation in vivo. J Immunol 1999;163:3260-8.
29. Huang YM, Hussein Y, Yarilin D, Xiao BG, Liu YJ, Link H. Interferon-beta induces the development of type 2 dendritic cells. Cytokine 2001;13:264-71.
30. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, Wei S, Krzysiek R, Durand-Gasselin I, Gordon A, Pustilnik T, Curiel DT, et al. Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7:1339-46.
31. Romani N, Gruner S, Brang D, Kampgen E, Lenz A, Trockenbacher B, Konwalinka G, Fritsch PO, Steinman RM, Schuler G. Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
32. + cells in cancer patients. Cancer Res 2000;60:1934-41.
33. Fanger NA, Maliszewski CR, Schooley K, Griffith TS. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 1999;190:1155-64.
34. Thomas R, Lipsky PE. Human peripheral blood dendritic cell subsets. Isolation and characterization of precursor and mature antigen-presenting cells. J Immunol 1994;153:4016-28.
35. Volpi I, Perruccio K, Tosti A, Capanni M, Ruggeri L, Posati P, Aversa F, Tabilio A, Romani L, Martelli MF, Velardi A. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 2001:97:2514-21.
36. O'Keeffe M, Hochrein H Vremec D, Pooley J, Evans R, Woulfe S, Shortman K. Effects of administration of progenipoietin 1, Flt-3 ligand, granulocyte colony-stimulating factor, and pegylated granulocyte-macrophage colony-stimulating factor on dendritic cell subsets in mice. Blood 2002;99:2122-30.
37. Parajuli P, Mosley RL, Pisarev V, Chavez J, Ulrich A, Varney M, Singh RK, Talmadge JE. Flt3 ligand and granulocyte-macrophage colony-stimulating factor preferentially expand and stimulate different dendritic and T-cell subsets. Exp Hematol 2001;29:1185-93.
38. von Mehren M, Arlen P, Gulley J, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S, Beard MT, Tsang KY, Schlom J, et al. The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res 2001;7:1181-91.
39. Maraskovsky E, Daro E, Roux E, Teepe M, Maliszewski CR, Hoek J, Caron D, Lebsak ME, McKenna HJ. In vivo generation of human dendritic cell subsets by Flt3 ligand. Blood 2000;96:878-84.
40. Pulendran B, Banchereau J, Burkeholder S, Kraus E, Guinet E, Chalouni C, Caron D, Maliszewski C, Davoust J, Fay J, Palucka K. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol 2000;165:566-72.
41. Morse MA, Nair S, Fernandez-Casal M, Deng Y, St Peter M, Williams R, Hobeika A, Mosca P, Clay T, Cumming RI, Fisher E, Clavien P et al. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J Clin Oncol 2000;18:3883-93.
42. Fong L, Hou Y, Rivas A, Benike C, Yuen A, Fisher GA, Davis MM, Engelman EG. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA 2001;98:8809-14.
43. Basak SK, Harui A, Stolina M, Sharma S, Mitani K, Dubinett SM, Roth MD. Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4. Blood 2002;99:2869-79.